AI and Drug Development: IP and data protection challenges - Webinar recording

19 December 2019

- Share by email
- Share on
- Twitter
- LinkedIn
- Get link
- Get QR Code

On Tuesday 19 November, a panel from our London life sciences team presented a webinar on what you need to know when using AI tools in drug development, in order to best protect your invention from an IP perspective, and avoid falling foul of EU and UK data protection laws.

Do you like what you are reading?

Please log-in or register to access Engage and set your preferences

New to Engage?

Create a free account for access to this publication and our vast catalogue of legal updates

Already Registered?

Log-in to continue reading

Log-in

Keywords artificial intelligence, drug design, life sciences, Healthcare, Data Protection

Languages English

Topics Patents, Trade Secrets and Confidential Know-how, Life Cycle Management of Pharmaceuticals and Biotechnology, Life Science Government Enforcement and Compliance, Clinical Trials

Countries Belgium, France, Germany, Hungary, Italy, Luxembourg, Netherlands, Poland, Spain, United Kingdom

This website is operated by Hogan Lovells Solutions Limited, whose registered office is at 21 Holborn Viaduct, London, United Kingdom, EC1A 2DY. Hogan Lovells Solutions Limited is a wholly-owned subsidiary of Hogan Lovells International LLP but is not itself a law firm. For further details of Hogan Lovells Solutions Limited and the international legal practice that comprises Hogan Lovells International LLP, Hogan Lovells US LLP and their affiliated businesses ("Hogan Lovells"), please see our Legal Notices page. © 2022 Hogan Lovells.

Attorney advertising. Prior results do not guarantee a similar outcome.